GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 14 Mar 2013.
V-raf murine sarcoma viral oncogene homolog B1
BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from
NCBI)
Sponsored links
Papers using
BRAF
antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on
BRAF
New targetable oncogenes in non-small-cell lung cancer.
New
Impact
Boston, United States. In J Clin Oncol, 10 Apr 2013
A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements.
Structural Basis of RIP1 Inhibition by Necrostatins.
New
China. In Structure, 05 Apr 2013
Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compound PLX4032.
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
New
Impact
Napoli, Italy. In Lancet Oncol, 31 Mar 2013
BACKGROUND: Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors.
An Unholy Alliance: Cooperation between BRAF and NF1 in Melanoma Development and BRAF Inhibitor Resistance.
New
Tampa, United States. In Cancer Discov, 31 Mar 2013
The first study from Maertens and colleagues describes a new transgenic mouse model in which mutant BRAF cooperates with NF1 loss to drive melanoma development through the abrogation of oncogene-induced senescence.
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
New
Impact
New York City, United States. In N Engl J Med, 14 Mar 2013
Nine patients had tumors with BRAF mutations, and 5 patients had tumors with mutations of NRAS.
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
New
Berlin, Germany. In Bioorg Med Chem Lett, 14 Mar 2013
Sulfamide 28 was identified as a highly potent MEK inhibitor with nanomolar cell potency against B-RAF (V600E) as well as Ras-mutated cell lines, high metabolic stability and resulting long half-lives.
Implementation of Universal Microsatellite Instability and Immunohistochemistry Screening for Diagnosing Lynch Syndrome in a Large Academic Medical Center.
New
Impact
Cleveland, United States. In J Clin Oncol, 11 Mar 2013
In approaches 2 and 3, patients were presumed to have sporadic CRC if the tumor lacked MLH1 expression and was also BRAF mutated or if the patient was diagnosed at age greater than 72 years and had no cancer family history.ResultsAbnormal MSI/IHC results occurred in 178 (16%) of 1,108 patients.
Direct detection of a BRAF mutation in total RNA from melanoma cells using cantilever arrays.
New
Impact
Basel, Switzerland. In Nat Nanotechnol, 28 Feb 2013
Malignant melanoma, the deadliest form of skin cancer, is characterized by a predominant mutation in the BRAF gene.
To BRAF or not to BRAF: is that even a question anymore?
Review
New
Lexington, United States. In J Neuropathol Exp Neurol, Jan 2013
Because the field has moved quickly during the past few years, there is not yet widespread awareness about what B-Raf normally does, how the BRAF gene is modified in gliomas, why mutant proteins promote gliomagenesis, and what an abnormal BRAF result means for diagnosis, prognosis, and treatment.
Adjuvant treatment of melanoma.
New
Sevilla, Spain. In Isrn Dermatol, Dec 2012
Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene.
[Treatment of metastatic melanoma: are we entering the era of targeted treatment?].
Review
New
Switzerland. In Praxis (bern 1994), Dec 2012
Around 60% of melanomas show a BRAF mutation and can be treated with selected tyrokinase inhibitors.
[Predictive biomarkers for anti-EGFR antibodies].
Review
New
Chiba, Japan. In Gan To Kagaku Ryoho, Nov 2012
Indeed, recent retrospective studies have shown that mutations in KRAS codon 61 and 146, BRAF, NRAS, and PIK3CA may also predict resistance to anti-EGFR antibodies in colorectal cancer patients.
[BRAF mutation testing for the choice of melanoma treatment].
Review
New
In Arkh Patol, Sep 2012
Approximately 50% of melanomas contain point mutation in codon 600 of the BRAF kinase.
[Colorectal carcinogenesis].
New
Ioánnina, Greece. In Bull Acad Natl Med, Mar 2012
Key characteristics of the serrated neoplasia pathway include BRAF gene mutations, excess CpG island methylation, and subsequent microsatellite instability.
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
GeneRIF
Erlangen, Germany. In Cancer Lett, 2012
BRAF mutations are of pathogenetic significance in wild type gastrointestinal stromal tumors.
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
GeneRIF
New York City, United States. In J Clin Invest, 2011
Murine thyroid tumors carrying the human BRAF(V600E) mutations are exquisitely dependent on the oncoprotein for viability.
[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Review
In Klin Onkol, 2011
The B-RAF kinase is among major targets of biological therapy of cancer.
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.
Impact
GeneRIF
Boston, United States. In Cell, 2011
Study genetically identifies multiple putative microRNA decoys for PTEN, validates ZEB2 mRNA as a bona fide PTEN ceRNA, and demonstrates that abrogated ZEB2 expression cooperates with BRAF(V600E) to promote melanomagenesis.
Mutation of IGFBP7 causes upregulation of BRAF/MEK/ERK pathway and familial retinal arterial macroaneurysms.
GeneRIF
Riyadh, Saudi Arabia. In Am J Hum Genet, 2011
The BRAF/MEK/ERK pathway is upregulated in progressive retinal arterial macroaneurysm patients, caused by mutation in IGFBP7.
BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.
GeneRIF
Athens, Greece. In Mol Cancer, 2010
BRAF mutation V600E significantly induces cell migration and invasion properties in vitro in colon cancer cells
